RxDoctor Payments Data

Alan Michels, MD

Internal Medicine · Payson, AZNPI 1376512129

Payments from drug & device makers

$807in general payments, 2019–2025

Across 22 payments — averaging $36.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pacira Pharmaceuticals Incorporated$465
  • Amgen$40
  • Lilly USA, LLC$33
  • Novo Nordisk$27
  • Novartis$27
  • Pfizer$26
  • plus $190 from 10 others

What the payments were for

  • Speaking & faculty fees$233%
  • Travel & lodging$46558%
  • Food & beverage$29837%
  • Education$213%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$807 in reported general payments places this provider in the 70th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$915,420
Medicare patients
74
Services billed
2,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban103$92,694
XareltoRivaroxaban43$51,899
TrulicityDulaglutide31$48,711
OzempicSemaglutide35$46,068
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$43,990
FarxigaDapagliflozin Propanediol25$25,559
JanuviaSitagliptin Phosphate33$23,390
MyrbetriqMirabegron30$18,824
Breo ElliptaFluticasone/Vilanterol21$15,993
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$14,004
Gabapentin249$6,431
Levothyroxine Sodium518$5,581
Tresiba Flextouch U-100Insulin Degludec11$4,803
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,979
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen103$3,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$92,694103 claims
GSKTrelegy Ellipta, Breo Ellipta$12$59,98354 claims
Johnson & JohnsonXarelto$12$51,89943 claims
Lilly USA, LLCTrulicity$33$48,71131 claims
Novo NordiskOzempic$27$46,06835 claims
Boehringer IngelheimStiolto Respimat$26$14,00423 claims
AbbVieSynthroid$18$1,61924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Payson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →